Management of Alzheimer disease

Today's options and tomorrow's opportunities

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The diagnosis of Alzheimer disease (AD) is made first by clinical criteria to establish progressive dementia and second by extensive laboratory evaluation to exclude other possible causes of dementia. There are no widely accepted biochemical markers to establish the presence of the disease in living patients. Sensitivity, specificity, and cost still limit the widespread use of single photon emission computerized tomography and positron emission tomography in diagnosis of the disease. Several cerebrospinal fluid markers, including amyloid β-protein precursor, are being developed to aid diagnosis and to use as surrogate markers for use during trials of therapy. Chromosomes 21, 14, and 19 genetic markers have recently been associated with or linked to AD. In the coming years, early identification of susceptibility or disease-causing genes may facilitate risk-factor modification or drug therapy to halt or at least delay disease onset. To date, therapy of AD has been limited to treating secondary behavioral symptoms. Recent studies of tacrine have shown significant improvement in cognition of treated patients, as demonstrated by neuropsychologic testing and global clinical measures. Several other approaches to treating AD are being developed. In the future, subgroups of AD may be identified by genetic markers that will each respond to specific modes of treatment.

Original languageEnglish
JournalAlzheimer Disease and Associated Disorders
Volume8
Issue numberSUPPL. 2
DOIs
StatePublished - 1994

Fingerprint

Alzheimer Disease
Genetic Markers
Dementia
Biomarkers
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 14
Tacrine
Chromosomes, Human, Pair 21
Behavioral Symptoms
Amyloid beta-Protein Precursor
Disease Susceptibility
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Cognition
Cerebrospinal Fluid
Therapeutics
Costs and Cost Analysis
Drug Therapy
Sensitivity and Specificity
Genes

Keywords

  • Alzheimer disease
  • Cerebrospinal fluid markers
  • Cholinergic
  • Diagnosis
  • Genetic markers
  • Treatment

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Management of Alzheimer disease : Today's options and tomorrow's opportunities. / Farlow, Martin.

In: Alzheimer Disease and Associated Disorders, Vol. 8, No. SUPPL. 2, 1994.

Research output: Contribution to journalArticle

@article{5e25ceacc12a41199edd8ba2a017e7b3,
title = "Management of Alzheimer disease: Today's options and tomorrow's opportunities",
abstract = "The diagnosis of Alzheimer disease (AD) is made first by clinical criteria to establish progressive dementia and second by extensive laboratory evaluation to exclude other possible causes of dementia. There are no widely accepted biochemical markers to establish the presence of the disease in living patients. Sensitivity, specificity, and cost still limit the widespread use of single photon emission computerized tomography and positron emission tomography in diagnosis of the disease. Several cerebrospinal fluid markers, including amyloid β-protein precursor, are being developed to aid diagnosis and to use as surrogate markers for use during trials of therapy. Chromosomes 21, 14, and 19 genetic markers have recently been associated with or linked to AD. In the coming years, early identification of susceptibility or disease-causing genes may facilitate risk-factor modification or drug therapy to halt or at least delay disease onset. To date, therapy of AD has been limited to treating secondary behavioral symptoms. Recent studies of tacrine have shown significant improvement in cognition of treated patients, as demonstrated by neuropsychologic testing and global clinical measures. Several other approaches to treating AD are being developed. In the future, subgroups of AD may be identified by genetic markers that will each respond to specific modes of treatment.",
keywords = "Alzheimer disease, Cerebrospinal fluid markers, Cholinergic, Diagnosis, Genetic markers, Treatment",
author = "Martin Farlow",
year = "1994",
doi = "10.1097/00002093-199424000-00006",
language = "English",
volume = "8",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Management of Alzheimer disease

T2 - Today's options and tomorrow's opportunities

AU - Farlow, Martin

PY - 1994

Y1 - 1994

N2 - The diagnosis of Alzheimer disease (AD) is made first by clinical criteria to establish progressive dementia and second by extensive laboratory evaluation to exclude other possible causes of dementia. There are no widely accepted biochemical markers to establish the presence of the disease in living patients. Sensitivity, specificity, and cost still limit the widespread use of single photon emission computerized tomography and positron emission tomography in diagnosis of the disease. Several cerebrospinal fluid markers, including amyloid β-protein precursor, are being developed to aid diagnosis and to use as surrogate markers for use during trials of therapy. Chromosomes 21, 14, and 19 genetic markers have recently been associated with or linked to AD. In the coming years, early identification of susceptibility or disease-causing genes may facilitate risk-factor modification or drug therapy to halt or at least delay disease onset. To date, therapy of AD has been limited to treating secondary behavioral symptoms. Recent studies of tacrine have shown significant improvement in cognition of treated patients, as demonstrated by neuropsychologic testing and global clinical measures. Several other approaches to treating AD are being developed. In the future, subgroups of AD may be identified by genetic markers that will each respond to specific modes of treatment.

AB - The diagnosis of Alzheimer disease (AD) is made first by clinical criteria to establish progressive dementia and second by extensive laboratory evaluation to exclude other possible causes of dementia. There are no widely accepted biochemical markers to establish the presence of the disease in living patients. Sensitivity, specificity, and cost still limit the widespread use of single photon emission computerized tomography and positron emission tomography in diagnosis of the disease. Several cerebrospinal fluid markers, including amyloid β-protein precursor, are being developed to aid diagnosis and to use as surrogate markers for use during trials of therapy. Chromosomes 21, 14, and 19 genetic markers have recently been associated with or linked to AD. In the coming years, early identification of susceptibility or disease-causing genes may facilitate risk-factor modification or drug therapy to halt or at least delay disease onset. To date, therapy of AD has been limited to treating secondary behavioral symptoms. Recent studies of tacrine have shown significant improvement in cognition of treated patients, as demonstrated by neuropsychologic testing and global clinical measures. Several other approaches to treating AD are being developed. In the future, subgroups of AD may be identified by genetic markers that will each respond to specific modes of treatment.

KW - Alzheimer disease

KW - Cerebrospinal fluid markers

KW - Cholinergic

KW - Diagnosis

KW - Genetic markers

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0028332699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028332699&partnerID=8YFLogxK

U2 - 10.1097/00002093-199424000-00006

DO - 10.1097/00002093-199424000-00006

M3 - Article

VL - 8

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - SUPPL. 2

ER -